Ligand Pharmaceuticals LGND Fair Value Measurement Disclosure
Fair Value Measurement Disclosure at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's fair value measurement disclosure.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's fair value measurement disclosure?
- Ligand Pharmaceuticals (LGND) reported fair value measurement disclosure of $352K in Q1 2026.
- How has Ligand Pharmaceuticals's fair value measurement disclosure changed year-over-year?
- Ligand Pharmaceuticals's fair value measurement disclosure decreased by 9.3% year-over-year, from $388K to $352K.
- What is the long-term trend for Ligand Pharmaceuticals's fair value measurement disclosure?
- Over 2 years (2023 to 2025), Ligand Pharmaceuticals's fair value measurement disclosure has grown at a 11.1% compound annual growth rate (CAGR), from $320K to $395K.
- What does fair value measurement disclosure mean?
- This represents the aggregate carrying amount of assets and liabilities that are measured at fair value on a recurring or non-recurring basis. It provides transparency into the valuation techniques and inputs used to determine these values, categorized by the fair value hierarchy. This is critical for asset managers holding diverse investment portfolios.